Hormone Use for Therapeutic Amenorrhea and Contraception During Hematopoietic Cell Transplantation.
There is a growing population of women who have or will undergo hematopoietic stem cell transplant for a variety of malignant and benign conditions. Gynecologists play an important role in addressing the gynecologic and reproductive health concerns for these women throughout the transplant process. As women undergo cell transplantation, they should avoid becoming pregnant and are at risk of uterine bleeding. Thus, counseling about and implementing hormonal treatments such as gonadotropin-releasing hormone agonists, combined hormonal contraceptives, and progestin-only methods help to achieve therapeutic amenorrhea and can serve as contraception during the peritransplant period. In this commentary, we summarize the timing, risks, and benefits of the hormonal options just before, during, and for the year after hematopoietic stem cell transplantation.
Department of Obstetrics and Gynecology, Northwestern Memorial Hospital, Chicago, Illinois; and the Medical Genetics Branch, National Human Genome Research Institute, and the Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
Katherine
K
Chang
Melissa A
MA
Merideth
Pamela
P
Stratton
D000568:Amenorrhea / Q000139:chemically induced*; D003267:Contraception; D004997:Ethinyl Estradiol / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008595:Menorrhagia / Q000188:drug therapy; D011247:Pregnancy
D004997:Ethinyl Estradiol